The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. “As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Related News Articles

Headline
President Biden March 13 announced the White House Challenge to Save Lives from Overdose, a national call to action for the public and private sectors to…
Headline
Released during National Eating Disorder Awareness week, the latest AHA People Matter, Words Matter poster encourages compassionate and caring language when…
Headline
The Substance Abuse and Mental Health Services Administration Feb. 8 issued a final rule implementing Coronavirus Aid, Relief, and Economic Security Act…
Headline
The Substance Abuse and Mental Health Services Administration Jan. 31 updated its Overdose Prevention and Response Toolkit, which includes basic information on…
Headline
The Substance Abuse and Mental Health Services Administration Jan. 31 issued a final rule that updates certain regulations for Opioid Treatment Programs and…
Headline
The House Dec. 12 voted 386-37 to pass AHA-supported legislation (H.R. 4531) that would reauthorize key SUPPORT Act programs for patients with substance use…